KERLONE
LOE ApproachingNDAORALTABLET
Approved
Oct 1989
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KERLONE is an oral small-molecule tablet approved in 1989 by Sanofi with an unknown mechanism of action and undisclosed indication(s). The drug's specific therapeutic class and patient population cannot be determined from available data.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30/100), indicating team consolidation and focus on generic transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked jobs reflect KERLONE's mature, non-growth status; roles available are primarily in managing the product's transition to generic competition and optimizing profitability in declining market share. Career mobility on this product is limited; professionals should expect portfolio rotation or redeployment to growth-stage assets.
Brand ManagerProduct Manager
Worked on KERLONE at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.